Pfizer announced on Tuesday that it had received all regulatory approvals to finalize its acquisition of Seagen, which it expects to close on Thursday.

In order to facilitate the integration of Seagen, the US pharmaceutical giant announced that it has decided to create a division entirely dedicated to oncology, which will combine the R&D and commercial assets of both groups.

Dr. Chris Boshoff will head up the division as Head of Oncology, reporting to Pfizer CEO Dr. Albert Bourla.

On the other hand, this reorganization will result in the departure of Angela Hwang, Pfizer's Commercial Director and Global President of Biopharmaceuticals, after a 27-year career with the company.

The commercial activities of the non-oncology businesses will be split between an American division, headed by Aamir Malik, and an international division headed by Alexandre de Germay, who will be returning to Pfizer after joining Sanofi and spending two years as head of Majorelle Laboratories.

Pfizer announced its intention to acquire Seagen earlier this year, based on a total enterprise value of $43 billion.

Copyright (c) 2023 CercleFinance.com. All rights reserved.